1-3 of 3
Brad H. Pollock
Close
Sort by
Journal Articles

P53 Based Strategy to Reduce Hematological Toxicity of Chemotherapy: Emerging Support from a Phase II Trial

Chul S. Ha, MD, Joel Michalek, PhD, Richard Elledge, MD, Kevin R. Kelly, MD, PhD, Suthakar Ganapathy, PhD, Hang Su, PhD, Carol Jenkins, RN, BSN, Athanassios Argiris, MD, Ronan Swords, MD, PhD, Tony Y. Eng, MD, Anand Karnad, MD, Richard Crownover, MD, PhD, Gregory P Swanson, MD, Martin Goros, M.S., Brad H Pollock, MPH, PhD, Zhi-Min Yuan, MD, PhD
Journal: Blood
Blood (2014) 124 (21): 4809.
https://doi.org/10.1182/blood.V124.21.4809.4809
Published: 2014
Journal Articles

A Cancer Survivorship Study of Perceptions Among Leukemia Patients In the Acute, Extended, and Permanent Survival Phases.

Devesh M. Pandya, MD, Sukeshi Patel, MD, Norma S Ketchum, MS, Brad H Pollock, MPH, PhD, Swaminathan Padmanabhan, MBBS, MD
Journal: Blood
Blood (2010) 116 (21): 1517.
https://doi.org/10.1182/blood.V116.21.1517.1517
Published: 2010
Journal Articles

Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study

Clinical Trials & Observations
Thomas C. Abshire, Brad H. Pollock, Amy L. Billett, Patricia Bradley, George R. Buchanan
Journal: Blood
Blood (2000) 96 (5): 1709–1715.
https://doi.org/10.1182/blood.V96.5.1709
Published: 2000